logo

A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems

Sector: Manufacturing (Industrial) • Location: Spain

Source: EU Funding & Tenders Portal

Project
Ended

Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology. It seemed impossible and costly to move a product developed in the laboratory to the industrial manufacturing of the product. To solve this issue Bionanoplus has developed and patented a highly versatile and easily scalable technology to enca

Project Information FAQ

Project Information

3 Q
The project “A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Spain. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology. It seemed impossible and costly to move a product developed in the laboratory to the industrial manufacturing of the product. To solve this issue Bionanoplus has developed and patented a highly versatile and easily scalable technology to encapsulate antigens and other molecules, called SAP-Nano. Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus it ensures an easy and inexpensive production of any scale, which can be performed using standard equipment and techniques. SAP-Nano technology has been successfully implemented with two clients, a fish vaccines manufacturer and a pharmaceutical company. Now Bionanoplus plan to launch his technology in the vaccines manufacturers market, firstly on to the PRRSV vaccines manufacturers market. It was estimated that losses due to PRRSV cost the swine industry EUR 1.5 billion per year in Europe and USD 664 million per year in the USA. SAP-Nano enables the development of unique vaccines, which are significantly more effective than conventional vaccines. Phase 1 of SME Instrument represents an opportunity to get a thorough business plan to minimize risks. The main objective is to perform a feasibility study to verify the economic viability in the vaccines manufacturers market and design a suitable business model, and the commercial, marketing and industrial strategies. The SAP-Nano proposal was presented for the first time to the 25-11-2015 call (NMP-25-2015-1-P) achieving a total score of 12,84. The lower point in the evaluation was Impact (score: 4.21). B+ has met potential clients in order to know the needs and requirement to develop new vaccines. The business case has also been improved. This new information has been included in this new submission of the proposal.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data